Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 17/20 | 0.65 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.56 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.49 |
| ▸ | INSR | P06213 | 2/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3710063 | 0.95 | TTK (0.72) | TTKPIK3CBMAPK8PTK2 | |
| SCHEMBL4768202 | 0.92 | TTK (0.58) | TTKPIK3CBMAPK8PTK2ALK | |
| SCHEMBL4766759 | 0.91 | TTK (0.70) | TTKPIK3CBMAPK8PTK2ALK | |
| SCHEMBL3714121 | 0.91 | TTK (0.79) | TTKPIK3CBMAPK8PTK2 | |
| SCHEMBL4768333 | 0.90 | TTK (0.58) | TTKPIK3CBMAPK8PTK2 | |
| SCHEMBL3703387 | 0.89 | TTK (0.63) | TTKPIK3CBMAPK8PTK2ALK | |
| SCHEMBL4767392 | 0.89 | TTK (0.63) | TTKPIK3CBMAPK8PTK2ALK | |
| SCHEMBL4768288 | 0.89 | TTK (0.62) | TTKPIK3CBMAPK8PTK2ALK | |
| SCHEMBL4768293 | 0.88 | TTK (0.56) | TTKPIK3CBMAPK8PTK2ALK | |
| SCHEMBL4768105 | 0.87 | TTK (0.62) | TTKPIK3CBMAPK8PTK2ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | TTK 4589/4885PIK3CB 2268/4885MAPK8 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.